

CAR T-cell Therapy Market Size Worth US\$ 21.8 Billion, Globally, by 2031 – Growth Report by Transparency Market Research

Increase in incidence of cancer is likely to boost the growth of the global CAR T-cell therapy market during the forecast period

WILMINGTON, DELAWARE, UNITED STATES, September 4, 2023

/EINPresswire.com/ -- The global [CAR T-Cell Therapy Market](#) According to the latest research study, the demand of global CAR T-Cell Therapy Market size & share in terms of revenue was valued at US\$ 1.1 Billion in 2020 and it is expected to surpass around US\$ 21.8 Billion mark by 2031, growing at a compound annual growth rate (CAGR) of approximately 30.6 % during the forecast period 2021 to 2031.

□□□ □□□ □□□□□□ □□□ □□□□□□□□□□
□□□□□□□□ □□□ □□□□□□□□□
□□□□□□□□□□□□ –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83242

The CAR T-cell therapy market is characterized by rapid advancements, transformative outcomes, and a commitment to improving the lives of cancer patients. As research and development continue to push the boundaries of what is possible, the market's trajectory holds the promise of reshaping the landscape of cancer treatment and offering renewed optimism to those affected by this devastating disease.

□□□□□□□□□□□ □□□□□□□□□ □□□□ □□□ □□□□□□□□:

The competitive landscape of the CAR T-cell therapy market has been studied in the report with



the detailed profiles of the key players operating in the market.

- Pfizer, Inc.
- Novartis AG
- Bristol-Myers Squibb
- Amgen, Inc.
- Sorrento Therapeutics, Inc.
- Johnson & Johnson Services, Inc.
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- bluebird bio, Inc.
- Other Prominent Players

Transparency Market Research provides detailed profiles of the key players operating in the market. - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83242

Transparency Market Research provides detailed profiles of the key players operating in the market.

- Rising Cancer Rates: The expansion of patient assistance programs, government efforts to boost cancer awareness, and a rising incidence of cancer all played pivotal roles in driving growth within the CAR-T cell therapy market during the forecast period.
- Recognizing the Promise of CAR-T Therapy: Biotechnology firms, major pharmaceutical corporations, and academic institutions have all recognized the potential of CAR-T cell therapy. These entities have made substantial investments in this domain to enhance production capabilities, expedite research and development, and broaden CAR-T therapy availability to a larger patient population.

Transparency Market Research provides detailed profiles of the key players operating in the market. - https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=83242

North America (U.S., Canada, Mexico)
Europe (France, Germany, UK, Russia, Rest of Europe)
Asia-Pacific (China, Japan, India, Rest of Asia-Pacific)
LAMEA (Latin America, Middle East, Africa)

Transparency Market Research provides detailed profiles of the key players operating in the market. - https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=83242

Transparency Market Research provides detailed profiles of the key players operating in the market.

Transparency Market Research provides detailed profiles of the key players operating in the market.

- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Lisocabtagene Maraleucel
- Idecabtagene Vicleucel
- Others

□□□□□□□□□□

- Acute Lymphocytic Leukemia
- Diffuse Large B-cell lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Others

□□□-□□□□

- Hospitals
- Cancer Treatment Centers

□□□□ □□□□□□□□ □□□□□□ □□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□□□ -

[Global Image-Based Cytometry in Cell Analysis Market](#) to Reach US\$ 6.5 Billion by 2031, Expanding at a CAGR of 10.4%:

[Ischemia Reperfusion Injury Therapeutics Market Revenue](#) to Cross USD 3.2 Billion by 2031 at a CAGR of 3.5%

Nikhil Sawlani
Transparency Market Research Inc.
+1 518-618-1030
[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/653680129>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.